OvaScience’s EggPC Technology Recognized by Science as a Top Ten Advancement in Reproductive Medicine

CAMBRIDGE, Mass.--()--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Science magazine has named OvaScience’s egg precursor cell (EggPCSM) technology, as described in the March 2012 Nature Medicine publication, one of the top ten papers in reproductive medicine. The publication challenged the existing paradigm that women are born with a set number of eggs, and demonstrated for the first time that EggPCs found on the ovaries can be matured into young, healthy eggs. The article by OvaScience co-founder, Jonathan Tilly, Ph.D., was recognized as part of a December 2013 supplement in Science.

“This seminal paper on EggPCs and the research that led to its publication have played a fundamental role in the development of our fertility product pipeline,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “We’re honored that the paper has been recognized and that its findings are contributing to the advancement of reproductive medicine as we develop new treatment options for the millions of women facing infertility.”

The Science supplement, titled “Ten Critical Topics in Reproductive Medicine” provides a broad review of papers selected by an expert panel as the most impactful journal articles in the field.

About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPCSM), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation in vitro fertilization (IVF) technologies. The Company currently has two product candidates in development: OvaTureSM, which seeks to create mature fertilizable eggs from a woman’s own EggPCs without the need for hormone injections, and AUGMENTSM, which aims to improve egg quality and increase the success of IVF. OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the prospects for the Company’s technology in addressing female infertility and the Company’s strategy, future plans and prospects, including statements regarding the planned discovery, development and commercialization of the Company’s product candidates. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”aim,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

Contacts

OvaScience, Inc.
Theresa McNeely, 617-299-7356
EVP, Strategic Corporate Communications
tmcneely@ovascience.com

Release Summary

OvaScience’s EggPC Technology Recognized by Science as a Top Ten Advancement in Reproductive Medicine

Sharing

Contacts

OvaScience, Inc.
Theresa McNeely, 617-299-7356
EVP, Strategic Corporate Communications
tmcneely@ovascience.com